Alcohol Use Disorder Treatment Market Size in the 7MM was ~USD 620 Million in 2023, estimated DelveInsight

Alcohol Use Disorder Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Alcohol Use Disorder Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight's "Alcohol Use Disorder Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Alcohol Use Disorder, historical and forecasted epidemiology as well as the Alcohol Use Disorder market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Alcohol Use Disorder Market by downloading the comprehensive report from DelveInsight @ Alcohol Use Disorder Treatment Market Size [https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Alcohol Use Disorder Market Report

* In September 2024:- Imbrium Therapeutics- A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Consumption in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment. The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.
* In September 2024:- Beckley Psytech Limited- An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.
* In September 2024:- Novo Nordisk A/S- The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
* The increase in Alcohol Use Disorder market size is a direct consequence of expected increase in patient population of AUD in the 7MM.
* As per DelveInsight analysis, the 12-month diagnosed prevalent cases of AUD in the 7MM were found to be approximately 25,312,290 cases in 2023, which are expected to increase by 2034.
* According to estimates based on DelveInsight's analysis, the US accounted for nearly 58.68% of the total 12-month diagnosed prevalent cases of AUD in the 7MM in the year 2023, which are expected to increase further by 2034.
* According to estimates based on DelveInsight's epidemiology model for AUD, the gender distribution of the disease suggests a male predominance across the 7MM, with approximately 9,354,525 males and 5,498,643 female cases in the US in 2023.
* The leading Alcohol Use Disorder Companies such as Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, Alkermes, Lundbeck, Otsuka Pharmaceuticals , and others
* Promising Alcohol Use Disorder Therapies such as Sunobinop, BPL-003, Psilocybin, CMND-100, Baclofen Tablets, Brexanolone, XR-NTX 380 mg, intramuscular injection, and others.

Gain a competitive edge in the Alcohol Use Disorder Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Alcohol Use Disorder Treatment Drugs [https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Alcohol Use Disorder Epidemiology Segmentation in the 7MM

* Alcohol Use Disorder Gender-specific Diagnosed Prevalent Cases
* Total 12-month Alcohol Use Disorder Diagnosed Prevalent Cases
* Alcohol Use Disorder Type-specific Diagnosed Prevalent Cases

Alcohol Use Disorder Market Insights

The considerable heterogeneity of AUD patients makes it especially challenging to design a single drug capable of treating AUD. The trajectory of alcohol use from occasional, through habitual to daily is a complex interplay between genetic vulnerabilities, environmental factors, and habitual and learned behaviors. Management of patients presenting with AUD has to be tailored depending on the presenting complaint, the level and duration of use, the severity of dependence, the presence of any additional comorbid substance use disorders, and the current physical and/or mental health conditions along with the motivation to change. Management always needs to start with the engagement of the patient in the process and understanding their initial goals for treatment. Following this, the focus of treatment may be on reduction of use, medically assisted withdrawal, or relapse prevention.

Discover key developments and opportunities in the Alcohol Use Disorder Market. Click here to learn more from DelveInsight's latest report @ Alcohol Use Disorder Market Size [https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Alcohol Use Disorder Treatment Market Landscape

The mainstay of AUD treatment is psychosocial intervention. However, unfortunately, the relapse rate is higher with psychosocial intervention alone as compared to in combination with pharmacotherapy. Thus most pharmacotherapies are used in conjunction with psychosocial treatment, to reduce relapse rates. The main goal of AUD treatment is either complete abstinence or reduction of heavy drinking (harm reduction), which is a proxy marker for harmful alcohol-related psychosocial consequences. Although controversy exists as to which is the preferred goal of AUD treatment, both options have benefits.

Alcohol Use Disorder Emerging Therapies and Companies

* AD04 (ondansetron): Adial Pharmaceuticals
* CORT 118335 (miricorilant): Corcept Therapeutics
* Psilocybin: Clairvoyant Therapeutics
* CMND-100: Clearmind Medicine
* BP1.3656: Bioprojet

Download DelveInsight's Alcohol Use Disorder Market report today and stay ahead in this rapidly evolving field. @ Alcohol Use Disorder Clinical Trials [https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Alcohol Use Disorder Market Report

* Coverage- 7MM
* Alcohol Use Disorder Companies- Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, Alkermes, Lundbeck, Otsuka Pharmaceuticals, and others
* Alcohol Use Disorder Therapies- Sunobinop, BPL-003, Psilocybin, CMND-100, Baclofen Tablets, Brexanolone, XR-NTX 380 mg, intramuscular injection, and others.
* Alcohol Use Disorder Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Alcohol Use Disorder Unmet Needs, KOL's views, Analyst's views, Alcohol Use Disorder Market Access and Reimbursement

Download the report to understand which factors are driving Alcohol Use Disorder Market Trends @ Alcohol Use Disorder Market Trends [https://www.delveinsight.com/sample-request/alcohol-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 AUD Market Overview at a Glance

4 AUD Market: Future Perspective

5 Executive Summary of AUD

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs

12 AUD: Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alcohol-use-disorder-treatment-market-size-in-the-7mm-was-usd-620-million-in-2023-estimated-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.